John T. Mullen, MD
Visiting Surgeon, Department of Surgery
Director, General Surgery Residency Program
- Surgical Oncology
- Department of Surgery
- Cancer Center
- Stomach Cancer
- Sarcoma and Connective Tissue Oncology
- Gastrointestinal Cancers
- Digestive Healthcare Center
- Swallowing and Heartburn Center
- Clinical Interests
- Soft tissue sarcoma
- Stomach (gastric) cancer
- Retroperitoneal sarcoma
- Gastrointestinal stromal tumor (GIST)
- Carcinoid tumor
- Desmoid tumor
- Gastrointestinal cancer
- Boston: Massachusetts General Hospital
- Medical Education
- MD, University of California Davis School of Medicine
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
- Fellowship, University of Texas - MD Anderson Cancer Center
- Board Certifications
- Surgery, American Board of Surgery
- Accepting New Patients
- Insurances Accepted
- Aetna Health Inc.
Blue Cross Blue Shield - Blue Care 65
Blue Cross Blue Shield - Indemnity
Blue Cross Blue Shield - Managed Care
Blue Cross Blue Shield - Partners Plus
Cigna (PAL #'s)
Fallon Community HealthCare
Great-West Healthcare (formally One Health Plan)
Harvard Pilgrim Health Plan - ACD
Harvard Pilgrim Health Plan - PBO
Health Care Value Management (HCVM)
Humana/Choice Care PPO
Neighborhood Health Plan - ACD
Neighborhood Health Plan - PBO
OSW - Maine
OSW - New Hampshire
OSW - Rhode Island
OSW - Vermont
Private Health Care Systems (PHCS)
Railroad Medicare - ACD
Tufts Health Plan
United Healthcare (non-HMO) - ACD
United Healthcare (non-HMO) - PBO
ResearchI am active in clinical and translational research in an effort to optimize the treatment and outcomes of patients with soft tissue sarcomas, desmoid tumors, and cancers of the stomach.
Current Translational Research Projects:
Principal Investigator. Comparative Genomics of Retroperitoneal Liposarcoma.
Current Prospective Clinical Trials:
Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) with Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas.
Phase I Trial of Bevacizumab, Metronomic Doxorubicin, and Radiation Therapy for Resectable Soft Tissue Sarcomas.
View my most recent publications at PubMed
Ahmad R, Schmidt BH, Rattner DW, Mullen JT. Factors influencing readmission after curative gastrectomy for gastric cancer. J Am Coll Surg 2014;218:1215-1222.
Schoenfeld JD, et al. The impact of positive margins on outcome among patients with gastric cancer treated with radiation. Am J Clin Oncol 2014;Feb 26 (epub ahead of print).
Look-Hong NJ, Hornicek FJ, Harmon DC, et al. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: A 10-year single institution retrospective study. Eur J Cancer 2012;49:875-883.
Mullen JT et al. b-Catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist 2013;18:1043-1049.
Mullen JT et al. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy. Cancer 2014.
Surgical Oncology Associates
55 Fruit Street
Boston, MA 02114-2696
U.S. News & World Report ranks Mass General gastroenterology third among U.S. hospitals.